#USA #San Diego #ASCCP #HPV Screening #PHASE Scientific

PHASE Scientific's Groundbreaking Achievement at the 2025 ASCCP Scientific Meeting

PHASE Scientific (PHASE) celebrated a monumental achievement during its debut at the 2025 American Society for Colposcopy and Cervical Pathology (ASCCP) Annual Scientific Meeting held in San Diego from April 24–26. This event is renowned for its critical contributions to women's health, focusing on advancements in cervical cancer prevention and diagnosis.

At this year’s gathering, PHASE showcased its innovative urine-based HPV testing technologies alongside research from the Peking University Shenzhen Hospital (PUSH), which received the prestigious Thomas V. Sedlacek, MD, Prize for Best Clinical Research Abstract. This accolade underscores the remarkable impact of the collaborative study exploring non-invasive methods for detecting HPV—human papillomavirus—a significant contributor to cervical cancer.

The study incorporated PHASE’s proprietary technologies, particularly highlighting the advanced urine DNA concentration method called PHASiFY™ and the PhaseLab™ HPV Urine Test. Researchers demonstrated these technologies' efficacy in a clinical setting involving women receiving follow-up care for high-grade cervical lesions (CIN2/3). Participants provided both urine samples and physician-collected samples, leading to an impressive concordance rate exceeding 97% between the urine-based PhaseLab™ testing and the Cobas 4800 standard for identifying HPV types 16 and 18, along with comparable detection rates for precancerous cervical lesions.

Dr. Ricky Chiu, Chairman and CEO of PHASE Scientific, stated, "We are proud that PHASE Scientific's technologies supported this important research presented by Peking University Shenzhen Hospital at the ASCCP Scientific Meeting. The findings reflect significant advancements in cervical precancer detection through convenient, non-invasive urine samples, marking a transformative step that makes cervical cancer screening more accessible."

The remarkable findings sparked extensive discussions among leading industry experts and healthcare professionals, amplifying the momentum for non-invasive methodologies in cervical cancer diagnostics. PHASE’s contribution is vital to overcoming traditional barriers associated with cervical cancer screening, paving the way for broader accessibility and patient-centric solutions in women’s health.

As cervical cancer remains a prominent public health issue, the emphasis on innovative screening methods highlights the urgent need for advancements that not only enhance detection but also streamline the screening processes for patients. With PHASE's commitment to innovation, the company is poised to lead the charge in transforming how cervical cancer is approached in clinical settings, ultimately aiming for a future where cervical cancer is no longer a public health threat.

It is essential to note that while the PhaseLab™ HPV Urine Test is available in the United States for HPV DNA detection, it has not been approved for cervical cancer screening. Nevertheless, the research presented lays the groundwork for future studies that could further validate the effectiveness of urine-based screening in clinical practice.

PHASE Scientific continues to pioneer diagnostics in the realm of cancer and infectious diseases, with operations expanding across the U.S., mainland China, and Hong Kong. The organization remains dedicated to innovating healthcare solutions that empower better disease detection and management, seeking to inspire a new standard of health through its advanced diagnostic tools.

This award not only reflects the scientific community's recognition of PHASE’s significant contributions to women's health but also marks a step forward in the collective effort to improve health outcomes for women worldwide. As the healthcare landscape continues to evolve, collaborations like these will play a crucial role in reshaping the future of cervical cancer screening and ensuring that essential services are accessible to all women.